JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia

Small molecular compounds in development for rheumatoid arthritis

(2013) Ronald F. van Vollenhoven   CURRENT OPINION IN RHEUMATOLOGY

Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex

(2013) Min Chen et al.   JNCI-Journal of the National Cancer Institute

Conditional Deletion of Jak2 Reveals an Essential Role in Hematopoiesis throughout Mouse Ontogeny: Implications for Jak2 Inhibition in Humans

(2013) Sung O. Park et al.   PLoS One

Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F

(2013) L Ma et al.   Blood Cancer Journal

Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2V617F in mice

(2012) C. Walz et al.   BLOOD

Diverging fates of cells of origin in acute and chronic leukaemia

(2012) Boris Kovacic et al.   EMBO Molecular Medicine

Targeting JAK2 in the therapy of myeloproliferative neoplasms

(2012) Mamatha M Reddy et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

The JAK-STAT Pathway at Twenty

(2012) George R. Stark et al.   IMMUNITY

BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia

(2012) Oliver Hantschel et al.   Nature Chemical Biology

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

(2011) A. Hamilton et al.   BLOOD

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia

(2011) W. Warsch et al.   BLOOD

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression

(2011) C. M. Lucas et al.   BLOOD

Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2

(2011) A V Purandare et al.   LEUKEMIA

Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors

(2011) E Traer et al.   LEUKEMIA

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

(2011) S Hart et al.   LEUKEMIA

Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML

(2011) Rajesh R. Nair et al.   LEUKEMIA RESEARCH

Comprehensive analysis of kinase inhibitor selectivity

(2011) Mindy I Davis et al.   NATURE BIOTECHNOLOGY

Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms

(2011) Y Nakaya et al.   Blood Cancer Journal

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

(2010) A. Quintas-Cardama et al.   BLOOD

JAK2 inhibitors: What's the true therapeutic potential?

(2010) Fabio P.S. Santos et al.   BLOOD REVIEWS

A Specific Need for CRKL in p210BCR-ABL-Induced Transformation of Mouse Hematopoietic Progenitors

(2010) J.-H. Seo et al.   CANCER RESEARCH

Targeted Blockage of Signal Transducer and Activator of Transcription 5 Signaling Pathway with Decoy Oligodeoxynucleotides Suppresses Leukemic K562 Cell Growth

(2010) Xiaozhong Wang et al.   DNA AND CELL BIOLOGY

Stat5 is indispensable for the maintenance ofbcr/abl-positive leukaemia

(2010) Andrea Hoelbl et al.   EMBO Molecular Medicine

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors

(2010) D K Hiwase et al.   LEUKEMIA

Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia

(2010) A Samanta et al.   LEUKEMIA

Advances in Understanding and Management of Myeloproliferative Neoplasms

(2009) A. M. Vannucchi et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors

(2009) Michael Hedvat et al.   CANCER CELL

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

(2009) A Pardanani et al.   LEUKEMIA

Jak2 inhibition deactivates Lyn kinase through the SET–PP2A–SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients

(2009) A K Samanta et al.   ONCOGENE

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells

(2008) J. Wu et al.   BLOOD

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera

(2008) Gerlinde Wernig et al.   CANCER CELL

Cytokine Signaling Modules in Inflammatory Responses

(2008) John J. O'Shea et al.   IMMUNITY

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells

(2008) Liang L. Zhou et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders

(2008) C Walz et al.   LEUKEMIA

Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance

(2008) Nadine N. Bewry et al.   MOLECULAR CANCER THERAPEUTICS

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY

Inteferons pen the JAK–STAT pathway

(2008) Christian Schindler et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Canonical and non-canonical JAK–STAT signaling

(2008) Willis X. Li   TRENDS IN CELL BIOLOGY